We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Immupharma Plc | LSE:IMM | London | Ordinary Share | GB0033711010 | ORD 1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.055 | -2.52% | 2.125 | 2.05 | 2.20 | 2.25 | 2.10 | 2.20 | 2,365,381 | 16:35:02 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Finance Services | 0 | -3.81M | -0.0114 | -1.89 | 7.17M |
Date | Subject | Author | Discuss |
---|---|---|---|
22/1/2018 12:12 | QQ: does anyone know if Abbvie has a lupus treatment? From a scan of there website it seems not. .Also noted that Humira costs 4730 dollars per month 56,000 a year,and that it came off patent in 2016. It still reached frightening sales figures. Pharma never ceases to stop astounding me at times. | l0ngterm | |
22/1/2018 12:01 | gbh2, the argument could go that 99.9% of BB posts have zero impact of affect on the share price...yet people are on here consistently day after day posting away | sportbilly1976 | |
22/1/2018 12:00 | stealth wealth 22 Jan '18 - 10:47 - 10492 of 10498 Looking at the numbers, Lupuzor has the potential to become the world's best selling drug. Only needs 650k patients out of the 2 million IMM's Tim McC says they could target, at $25k pa to give $16.25 billion pa sales, even without the other indications the P140 platform (of which Lupuzor is a part) could treat. If I know this, so will all the big pharmas with the money to do a very large deal or takeover. N.B. Abbvie’s Humira (adalimumab) is the world's best-selling drug with sales of US $16.078 billion in 2016. (Treats rheumatoid arthritis and Crohns, similar to IMM's P140 platform). | racey5 | |
22/1/2018 11:59 | njb I just feel a need to respond to deramping posts like from yourself. | racey5 | |
22/1/2018 11:59 | Can't help but wonder why anyone would be daft enough to think ramping on advfn would affect the SP! racey5 22 Jan '18 - 11:48 - 10499 of 10500 (Filtered) | gbh2 | |
22/1/2018 11:52 | racey5 Member since today. Another of the ramping gang aliases. Funny how money maker, top tips, hotting up, stealth wealth, runtoma and now racey5 copy and paste the same content. | njb67 | |
22/1/2018 11:48 | stealth wealth 22 Jan '18 - 10:47 - 10492 of 10498 Looking at the numbers, Lupuzor has the potential to become the world's best selling drug. Only needs 650k patients out of the 2 million IMM's Tim McC says they could target, at $25k pa to give $16.25 billion pa sales, even without the other indications the P140 platform (of which Lupuzor is a part) could treat. If I know this, so will all the big pharmas with the money to do a very large deal or takeover. N.B. Abbvie’s Humira (adalimumab) is the world's best-selling drug with sales of US $16.078 billion in 2016. (Treats rheumatoid arthritis and Crohns, similar to IMM's P140 platform). | racey5 | |
22/1/2018 11:44 | This could be a real winner. | racey5 | |
22/1/2018 11:40 | Each to his own strategy. Happy sitting on these and adding on decent pull backs, worked well since 52p | ny boy | |
22/1/2018 11:19 | I don't think I would worry about missing the next 10% or so given that it hopefully won't be the big move. Still a bit of time. But may be wrong. | makingmillions | |
22/1/2018 11:07 | Have you seen how many sudden 10% or 20% leg ups we have had in the last 3 months? Anyone that wants to get involved, but is sitting on the sidelines needs their head read if you ask me. | qazwsxedc69 | |
22/1/2018 10:54 | Yes, can see the other options there Lord Gnome. Should probably come clearer fairly soon. Thanks. | makingmillions | |
22/1/2018 10:51 | Well said sw. | englishlongbow | |
22/1/2018 10:47 | Looking at the numbers, Lupuzor has the potential to become the world's best selling drug. Only needs 650k patients out of the 2 million IMM's Tim McC says they could target, at $25k pa to give $16.25 billion pa sales, even without the other indications the P140 platform (of which Lupuzor is a part) could treat. If I know this, so will all the big pharmas with the money to do a very large deal or takeover. N.B. Abbvie’s Humira (adalimumab) is the world's best-selling drug with sales of US $16.078 billion in 2016. (Treats rheumatoid arthritis and Crohns, similar to IMM's P140 platform). | stealth wealth | |
22/1/2018 10:45 | It could go any way from here, makingmillions. Head and Shoulders, Double Top, or a Breakout (my preferred outcome). My own view is that the market will wait for the next news before any sustained move towards the sort of numbers that some posters on here talk about. £10 a share wouldn't make me a millionaire, but it would be a welcome contribution towards that goal. | lord gnome | |
22/1/2018 10:35 | Recall someone recently mentioned a head and shoulders pattern forming. A bit lopsided but could be ready for the downward leg now if it was going to happen. I think I will wait for confirmation either way before buying in again.Any Chartists with thoughts? | makingmillions | |
22/1/2018 10:27 | 4/12/15 20p 9/12/16 39p 29/12/17 170p "market doesn't buy this optimism yet" | qazwsxedc69 | |
22/1/2018 10:26 | thank you, Lgnome I am in the same situation. | jpleight | |
22/1/2018 10:21 | god, so touchy... | jpleight | |
22/1/2018 10:11 | no, I think many on here are 200% positively Gaga about giving you thumbs down for your posts 🤔 | ny boy | |
22/1/2018 10:10 | Flávio, What a comeback statement:-) | che7win | |
22/1/2018 10:09 | Jpleight....market doesnt buy this optimism yet...quite a statement when... We are 400% UP in 3 months | flavio_monteiro | |
22/1/2018 09:58 | market doesnt buy this optimism yet. | jpleight |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions